Form D · Pharmaceuticals
Sojournix, Inc.
Arlington, MA · CIK 0001674444
Offering snapshot reported Nov 13, 2018 · SEC filing
- Reported sold
- $44M Offering amount: $44M
- Investors reported
- 7 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Nov 1, 2018 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Nov 13, 2018 | Initial | $43,999,992 | No comparison | 7 | SEC filing |
| Dec 21, 2017 | Amendment | $19,028,100 | $13,028,100vs Aug 9, 2017 | 7 | SEC filing |
| Aug 9, 2017 | Initial | $6,000,000 | No comparison | 2 | SEC filing |
| May 18, 2017 | Amendment | $8,363,640 | $6,363,640vs May 17, 2016 | 3 | SEC filing |
| May 17, 2016 | Initial | $2,000,000 | No comparison | 2 | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-325591
Source: Form D, filed Nov 13, 2018. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Aaron Davis | Director |
| Martin Freed | Director |
| Daniel S. Grau | Director, Executive |
| Peter Kolchinsky | Director |
| Peter Lanciano | Director |
| Scott Rakestraw | Director |
Issuer details
Industry: Pharmaceuticals (See others in industry)
Address:
1167 Massachusetts Ave.
Arlington, MA, 02476
Arlington, MA, 02476